Preliminary results from a large clinical trial showed Roche's rheumatoid arthritis drug Actemra, or tocilizumab, can reduce mortality risk among hospitalized patients with severe COVID-19, particularly when taken together with the steroid dexamethasone. The findings also showed tocilizumab can shorten hospital length of stay and reduce the need for mechanical ventilation.